Company: MDCXW
Filing Date: 2025-06-23
Form Type: PRER14A
Source: 0001062993-25-012067
Chunk: 85

Company: Medicus Pharma Ltd.
Filing Date: 2025-06-23
Form: PRER14A
Chunk 85
---
00% Unsecured Convertible Notes due 2025 were subsequently converted, along with accrued and unpaid interest, into Common Shares.

<div align='center'>ADDITIONAL INFORMATION</div>

Additional information relating to the Company can be found on the SEC's website at www.sec.gov and on SEDAR+ at www.sedarplus.ca under the Company's issuer profile. Additional financial information is provided in the Company's comparative financial statements and Management Discussion & Analysis for the financial years ended December 31, 2024 and December 31, 2023. A copy of this document and other public documents of the Company are available upon request to 300 Conshohocken State Rd. Suite 200,W. Conshohocken, PA 19428.

<div align='center'>BOARD APPROVAL</div>

The contents and the sending of this proxy statements have been approved by the Board.

<div align='center'>64

SCHEDULE "A"
AMENDED ARTICLE 3.2 OF BY-LAW NO. 1</div>

3.2 Quorum at Meetings of Shareholders

A quorum for the transaction of business at any meeting of shareholders shall be 2 voting persons holding or representing in the aggregate not less than 33⅓% of the issued and outstanding shares of the Company, or of the class or classes respectively (if there is more than one class of shares outstanding for the time being). Notwithstanding the foregoing, if the Company has only one shareholder, or only one shareholder of any class or series of shares, the shareholder present in person or by proxy constitutes a meeting and a quorum for such meeting.

<div align='center'>SC A-1

SCHEDULE "B"
BOARD MANDATE

MEDICUS PHARMA LTD.
(the "Company")</div>

1.PURPOSE

1.1.The Board of Directors (the "Board") of the Company is responsible for the supervision of the senior management of the business, the going concern and general affairs of the Company. The Board shall conduct the procedures, and manage the responsibilities and obligations set out below, either directly or through committees of the Board, currently consisting of the Audit Committee and the Compensation and Governance Committee.

2.COMPOSITION

2.1.The Board should consist of individuals who possess skills and competencies in areas that are relevant to the business and affairs of the Company. At least a majority of the directors will be deemed to be "independent" directors within the meaning of applicable securities laws, instruments, rules